INTRALYMPHATIC GAD-ALUM (DIAMYD®) IMPROVES GLYCEMIC CONTROL IN TYPE 1 DIABETES PATIENTS CARRYING HLA DR3-DQ2

被引：0
|
作者：
Ludvigsson, J. [1 ,2 ]
Nowak, C. [3 ]
Hannelius, U. [4 ]
机构：
[1] Linkoping Univ, Crown Princess Victoria Childrens Hosp, Dept Biomed & Clin Sci, Linkoping, Sweden
[2] Linkoping Univ, Div Pediat, Dept Biomed & Clin Sci, Linkoping, Sweden
[3] Karolinska Inst, Dept Neurobiol, Vardvetenskap & Samhalle, Huddinge, Sweden
[4] Diamyd Med, Stockholm, Sweden
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP055 / #4
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [1] Intralymphatic GAD-Alum (Diamyd®) improves glycemic control in Type 1 diabetes patients carrying HLA DR3-DQ2
    Ludvigsson, J.
    Nowak, C.
    Hannelius, U.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [2] Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
    Nowak, Christoph
    Lind, Marcus
    Sumnik, Zdenek
    Pelikanova, Terezie
    Chavez, Lia Nattero
    Lundberg, Elena
    Rica, Itxaso
    Martinez-Brocca, Maria A.
    Ruiz de Adana, Mari Sol
    Wahlberg, Jeanette
    Hanas, Ragnar
    Hernandez, Cristina
    Clemente-Leon, Maria
    Gomez-Gila, Ana
    Ferrer Lozano, Marta
    Sas, Theo
    Pruhova, Stepanka
    Dietrich, Fabricia
    Marin, Sara Puente
    Hannelius, Ulf
    Casas, Rosaura
    Ludvigsson, Johnny
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (09): : 2644 - 2651
  • [3] Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
    Ulf Hannelius
    Craig A. Beam
    Johnny Ludvigsson
    [J]. Diabetologia, 2020, 63 : 2177 - 2181
  • [4] Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
    Hannelius, Ulf
    Beam, Craig A.
    Ludvigsson, Johnny
    [J]. DIABETOLOGIA, 2020, 63 (10) : 2177 - 2181
  • [5] HLA associations in type 1 diabetes among patients not carrying high-risk DR3-DQ2 or DR4-DQ8 haplotypes
    Undlien, DE
    Kockum, I
    Ronningen, KS
    Lowe, R
    Saanjeevi, CB
    Graham, J
    Lie, BA
    Akselsen, HE
    Lernmark, Å
    Thorsby, E
    [J]. TISSUE ANTIGENS, 1999, 54 (06): : 543 - 551
  • [6] HIGH RISK GENOTYPES HLA-DR3-DQ2/DR3-DQ2 AND DR3-DQ2/DR4-DQ8 IN CO-OCCURRENCE OF TYPE 1 DIABETES AND CELIAC DISEASE
    Schweiger, Darja Smigoc
    Mendez, Andrijana
    Jamnik, Sabina Kunilo
    Bratanic, Nina
    Bratina, Natasa
    Battelino, Tadej
    Brecelj, Jernej
    Vidan-Jeras, Blanka
    [J]. HLA, 2016, 87 (04) : 233 - 233
  • [7] Intralymphatic Administration of GAD-Alum in Type 1 Diabetes: a Long-term Follow-up
    Bitzer, Michaela
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2022, 17 (04) : 236 - 236
  • [8] High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence of type 1 diabetes and celiac disease
    Schweiger, Darja Smigoc
    Mendez, Andrijana
    Jamnik, Sabina Kunilo
    Bratanic, Nina
    Bratina, Natasa
    Battelino, Tadej
    Brecelj, Jernej
    Vidan-Jeras, Blanka
    [J]. AUTOIMMUNITY, 2016, 49 (04) : 240 - 247
  • [9] Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes
    Dietrich, Fabricia
    Barcenilla, Hugo
    Tavira, Beatriz
    Wahlberg, Jeanette
    Achenbach, Peter
    Ludvigsson, Johnny
    Casas, Rosaura
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2022, 38 (03)
  • [10] GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients
    Pihl, Mikael
    Barcenilla, Hugo
    Axelsson, Stina
    Cheramy, Mikael
    Akerman, Linda
    Johansson, Ingela
    Ludvigsson, Johnny
    Casas, Rosaura
    [J]. CLINICAL IMMUNOLOGY, 2017, 176 : 114 - 121
12345